The molecular targets of Kangai injection in gastric cancer by in silico network pharmacology approach and experiment confirmation

J Appl Biomed. 2023 Sep;21(3):150-159. doi: 10.32725/jab.2023.017. Epub 2023 Sep 22.

Abstract

Introduction: This study aimed to identify the phytochemical constituents that could target gastric cancer in Kangai injection using a network pharmacology-based approach.

Methods: Protein-protein interactions (PPI), Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were conducted utilizing String and OmicShare tools. In the in vitro experiments, the related mRNA and protein levels were assessed via real-time quantitative polymerase chain reaction and Western blotting, respectively. Cell proliferation was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay.

Results: Kangai injection comprises several compounds, which target multiple substrates and pathways related to gastric cancer. The PPI and Gene Ontology analyses revealed that tumor necrosis factor (TNF) was a hub gene. KEGG pathway enrichment analysis indicated that the the TNF pathway was significantly enriched. Kangai injection decreased the mRNA levels of TNFR2, TRAF2, PI3K, AKT, and IκBα and inhibited the phosphorylation of PI3K, AKT, and IκBα phosphorylations. Kangai injection inhibited cell proliferation, while TNFR2 overexpression or treatment with the PI3K activator 740 Y-P partially restored it.

Conclusion: Kangai injection operates through multiple targets and pathways in gastric cancer, with the TNFR2/PI3K/AKT/NF-κB pathway playing a crucial role in its mechanism against gastric cancer.

Keywords: Gastric cancer; Kangai injection; Network pharmacology; TNF pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • NF-KappaB Inhibitor alpha
  • Network Pharmacology
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt
  • Receptors, Tumor Necrosis Factor, Type II
  • Stomach Neoplasms* / drug therapy
  • Stomach Neoplasms* / genetics
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • NF-KappaB Inhibitor alpha
  • Receptors, Tumor Necrosis Factor, Type II
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt
  • Tumor Necrosis Factor-alpha